J&J Beats on Tremfya Strength as Mideast Conflict Hits Devices
Johnson and Johnson posted third-quarter adjusted earnings of $2.59 a share on revenue of $25.4 billion, clearing Wall Street targets of $2.54 and $25
Tremfya
Every Fin-node story mentioning Tremfya — 1 story, newest first.
Tremfya · 1 story